ライフサイエンスコーパス: GH

1 GH accelerated growth and improved mineralization and th

2 GH activates agouti-related protein (AgRP) neurons and G

3 GH administration exacerbated adverse BD-associated effe

4 GH excess leads to decreased colon cell phosphatase and

5 GH receptor (GHR) antagonist therapy is more effective b

6 GH remains unchanged.

7 GH should be given at dosages of 0.045-0.05 mg/kg per da

8 GH treatment increased femur BMD and lean body mass but

9 GH treatment increased serum IGF-I levels similarly in T

10 GH treatment increased vertebral Tb. bone mass in Contro

11 GH treatment is not appropriate in rat liver transplant

12 GH was 20% larger among the cases at enrollment (3.16 cm

13 GH, IGF-1 and IGFBP-2 levels were evaluated by ELISA at

14 GH, IGF-1, and IGFBP-2 were not correlated with insulin

15 GH-C53S was exclusively stained in the Golgi apparatus,

16 GH-deficient prophet of pituitary-specific positive tran

17 GH-releasing hormone (GHRH) neurons express estrogen rec

18 GH-responsive cells were detected via the phosphorylated

19 GH-secreting tumors had a high frequency of whole chromo

20 growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis.

21 transducer and activator of transcription 5 (GH-Stat5) signaling compared to wild-type mice.

22 A GH carrier containing OP3-4 with BMP-2 was subperiosteal

23 elicited by an increase in plasma ghrelin, a GH secretagogue.

24 rted through increased amounts of ghrelin, a GH stimulator.

25 Administration of a GH receptor (GHR) blocker in acromegaly patients induced

26 ted with increased levels of somatostatin, a GH inhibitor, whereas the deleterious effect on nonsteat

27 726,023 short-read sequences matching with a GH domain-containing protein were located outside the do

28 anism in transgenic mice results in aberrant GH secretion and body growth.

29 yl]-S-phenyl glycine t-butylester) abrogates GH-induced epithelial to mesenchymal transition (EMT) an

30 ry cultures using forskolin or a long-acting GH-releasing hormone (GHRH) analog increased GH producti

31 TAT5 phosphorylation (pSTAT5) after an acute GH injection.

32 ptor ligand that targets somatotroph adenoma GH secretion in patients with acromegaly, inhibited cAMP

33 elopment of fatty liver depends on adipocyte GH signaling.

34 clampsia) and 1.81 (95% CI, 1.44-2.27) after GH vs no HDP.

35 54 years and 5.08 (95% CI, 1.80-14.34) after GH vs no GH.

36 mortality was 1.57 (95% CI, 1.04-2.39) after GH vs no GH.

37 or eclampsia, 1.51 (95% CI, 1.27-1.80) after GH vs no HDP, 1.62 (95% CI, 1.46-1.79) after preterm del

38 Catecholamines are known to alter GH secretion and neurons expressing TH are located in se

39 ent of idraparinux and its C5'-epi analogue (GH unit) has been developed.

40 In mice, ruxolitinib decreased basal and GH-stimulated STAT5 phosphorylation in adipose tissue.

41 patients with acromegaly, inhibited cAMP and GH and reversed DNA damage induction.

42 As somatotroph differentiation and GH secretion are dependent on cAMP activation and we pre

43 in 14 steps into the fully protected EF and GH disaccharide fragments.

44 with stronger associations when both GDM and GH were present.

45 Somatostatin, ghrelin, and GH-releasing hormones that regulate GH secretion from th

46 ne (GH) is secreted during hypoglycemia, and GH-responsive neurons are found in brain areas containin

47 es agouti-related protein (AgRP) neurons and GH receptor (GHR) ablation in AgRP cells mitigates highl

48 which induces somatotroph proliferation and GH secretion, may concomitantly induce DNA damage, poten

49 GHRH neurons were found to coexpress TH- and GH-induced pSTAT5.

50 Specifically, we compared wild-type and GH-transgenic fish, the latter achieving either enhanced

51 acid (RGD) motif in the exposed, antigenic, GH loop of capsid protein VP1.

52 This hGH molecule (hereafter referred to as GH-C53S) lacks the disulfide bond between p.Cys-53 and p

53 ing neurons that is critical to autoregulate GH secretion via a negative-feedback loop.

54 al analysis of a carbocyclic mechanism-based GH inactivator, the results of which show that the two M

55 Because GH developed evenly from 20 weeks gestation, and PE occu

56 ta strongly support a potential link between GH, which wanes with age, and impaired macrophage functi

57 ne (GH) secretion is primarily controlled by GH-releasing hormone and somatostatin neurons.

58 to persistent GH stimulation are dictated by GH/STAT5-regulated transcription factors arranged in a h

59 olled by negative-feedback loops mediated by GH-releasing hormone (GHRH)- or somatostatin-expressing

60 Microbiomes were generally more variable by GH in stressed bees, which also showed opposing and comp

61 intestine and cecum displayed characteristic GH profiles matching distinct microbial assemblages.

62 Chronic GH excess induces an equipoise insulin resistance in pat

63 Our study suggests that improved circulating GH and IGFBP-2 levels may mediate the beneficial effects

64 these cells to sense changes in circulating GH levels to adjust pituitary GH secretion within a narr

65 BD reduced circulating GH and increased GH levels only in steatotic livers.

66 By manipulating the highly conserved -GH- residues in the CGHC active site of PDI, we created

67 re located in several brain areas containing GH-responsive cells.

68 and epigenetic changes induced by continuous GH infusion (cGH) in male mice, which rapidly feminizes

69 In contrast, GH effect on expression of ALP, IGFBP5 and axin2 in bone

70 In comparison to untreated controls, GH-treated animals demonstrated enhanced median nerve re

71 UL (right hind limb) and treatment (3 mg/day GH or vehicle) began two weeks after the first TBI episo

72 Conversely, adiponectin decreased GH-release, and inhibited GHRH-, but not ghrelin-stimula

73 hyperphagic obesity, hypogonadism, decreased GH, and hypoinsulinemic diabetes due to impaired prohorm

74 kistani women were half as likely to develop GH, but as likely to develop PE than white British women

75 associated with a 34% increase in developing GH but a 33% reduction in the odds of PTB.

76 Criteria for diagnosing GH and PE may benefit from considering ethnic difference

77 S is 25.2% of that of GH-WT and that dimeric GH-C53S-His has no significant bioactivity in cell proli

78 tion sequence leading to l-ido disaccharide (GH unit) with a total yield of 24% (36% for the EF fragm

79 demonstrate a slow progression from elevated GH release to the formation of overt somatotropinomas in

80 thesized that keystone genes from the entire GH complement of Salmonella are required to degrade glyc

81 mes retrieved from MG-RAST for environmental GHs and identified 160,790 additional enzymes.

82 thickening and proteinuria induced by excess GH.

83 fibrosis, all of which are induced by excess GH.

84 d a mouse model in vivo, we show that excess GH activates Notch1 signaling in a gamma-secretase-depen

85 All these results confirm that excess GH induces Notch1 signaling in podocytes, which contribu

86 and the downstream pathways by which excess GH leads to diabetic nephropathy is not established.

87 in-releasing hormone (CRH) neurons expressed GH-induced pSTAT5, respectively.

88 at high resolution, attaches to an extended GH loop via interactions with the RGD motif plus downstr

89 The provision of extracellular GHs as public goods may influence microbial community dy

90 Glycoside hydrolase family (GH) 16 comprises a large and taxonomically diverse famil

91 CKD or on dialysis should be candidates for GH therapy if they have persistent growth failure, defin

92 al responses argue for an important role for GH in macrophage priming and maturation.

93 dent in humans and mice lacking a functional GH receptor (GHR).

94 ion, we found associations of a combined GDM/GH indicator with cardiometabolic disease in mothers and

95 We evaluated a combined GDM/GH risk indicator in both mothers and fathers because of

96 64,232 couples were categorized based on GDM/GH status (neither, either, or both).

97 has reduced bioactivity compared with WT GH (GH-WT) because of its decreased ability to bind and acti

98 nt improvement in the item "General Health" (GH) regarding quality of life at 3 (NPP: 70.5 +/- 15.2 v

99 Circulating and hepatic GH and EGF levels, hepatic damage, and regeneration para

100 KSR2) causes selective inhibition of hepatic GH signaling in neonatal mice with impaired expression o

101 s to dissect the mechanisms by which hepatic GH resistance leads to steatosis and overall insulin res

102 itative description of global heterogeneity (GH) and DH for samples and blending processes.

103 tionships between changes in genital hiatus (GH) and development of pelvic organ prolapse using data

104 ctin-levels, while CORT-KOs displayed higher GH- and lower prolactin-levels than controls under both

105 -diet conditions as SST-KOs presented higher GH/prolactin-levels, while CORT-KOs displayed higher GH-

106 Life-long lack of growth hormone (GH) action can produce remarkable extension of longevity

107 puberty, the serum levels of growth hormone (GH) and its downstream effector IGF-1 increase and play

108 However, growth hormone (GH) can also stimulate macrophage activation.

109 Growth hormone (GH) deficiency and loss of physical activity are common

110 h increasing levels of serum growth hormone (GH) during natural GH cycles.

111 Growth hormone (GH) has an important function as an insulin antagonist w

112 Growth hormone (GH) is a major metabolic homeostatic factor that is secr

113 Growth hormone (GH) is secreted during hypoglycemia, and GH-responsive n

114 unction caused by changes in growth hormone (GH) levels after brain death (BD), and the effects of mo

115 Growth hormone (GH) plays a significant role in normal renal function an

116 tment with recombinant human growth hormone (GH) promotes longitudinal growth and likely enables chil

117 that PVH neurons express the growth hormone (GH) receptor (GHR), although the role of GH signaling on

118 Gonadal steroids modulate growth hormone (GH) secretion and the pubertal growth spurt via undefine

119 assical studies suggest that growth hormone (GH) secretion is controlled by negative-feedback loops m

120 hat the pulsatile pattern of growth hormone (GH) secretion is primarily controlled by GH-releasing ho

121 Sex-dependent pituitary growth hormone (GH) secretory profiles-pulsatile in males and persistent

122 Here we show that central growth hormone (GH) signaling also promotes neuroendocrine adaptations d

123 Disruption of hepatocyte growth hormone (GH) signaling through disruption of Jak2 (JAK2L) leads t

124 tes the efficacy of systemic growth hormone (GH) therapy in ameliorating the deleterious effects of c

125 The ability of growth hormone (GH) to induce adipose tissue lipolysis has been known fo

126 utzfeldt-Jakob disease after growth hormone (GH) treatment provide an opportunity to understand facto

127 Growth hormone (GH), a pleiotropic hormone secreted by the pituitary gla

128 rtisol and high aldosterone, growth hormone (GH), and prolactin levels, thereby presumably fostering

129 ients have been treated with growth hormone (GH), and recent findings suggest that blocking fibroblas

130 releasing hormone (GHRH) and Growth hormone (GH), underappreciated findings in ARID1B patients.

131 a marked increase in plasma growth hormone (GH), which is elicited by an increase in plasma ghrelin,

132 entral hypogonadism, and low growth hormone (GH).

133 y-like behaviors compared with group housed (GH) rats.

134 the 191-amino-acid sequence of 22 kDa human GH (hGH) with serine (p.C53S).

135 of 513 pyranoside-bound glycoside hydrolase (GH) crystal structures, we determine that most glucosida

136 pace has revealed a new glycoside hydrolase (GH) family (GH164) of putative mannosidases.

137 he founding member of a glycoside hydrolase (GH) family, GH145.

138 proteins include five glycoside hydrolases (GHs) and one polysaccharide lyase, the genes for which w

139 ivities of PUL-encoded glycoside hydrolases (GHs) and surface glycan-binding proteins (SGBPs) for the

140 Glycoside hydrolases (GHs) catalyze hydrolyses of glycoconjugates in which the

141 The identification of glycoside hydrolases (GHs) for efficient polysaccharide deconstruction is esse

142 Glycoside hydrolases (GHs) have attracted considerable attention as targets fo

143 Focusing on Glycoside Hydrolases (GHs) we found that, across samples, 58.3% of the 4,726,0

144 containing multidomain glycoside hydrolases (GHs).

145 Salmonella contains 47 glycosyl hydrolases (GHs) that may degrade the glycan.

146 The incidence of gestational hypertension (GH) and pre-eclampsia (PE) is increasing.

147 ation, but data on gestational hypertension (GH) are limited.

148 mellitus (GDM) and gestational hypertension (GH) with cardiometabolic disease has not been well studi

149 H and calcium with gestational hypertension (GH), pre-eclampsia (PE), caesarean section (CS), preterm

150 n pregnancy (HDP) (gestational hypertension [GH], preeclampsia, or eclampsia) and 1.81 (95% CI, 1.44-

151 In summary, the unpaired Cys-165 in GH-C53S forms a disulfide bond linking two hGH molecules

152 nterneurons that are apt to sense changes in GH levels and regulate the somatotropic axis in mice.SIG

153 ar mass were the most consistent findings in GH and preeclampsia.

154 K-alpha and -gamma subunit-encoding genes in GH-transgenic fish achieving accelerated growth.

155 on of several AMPK subunit-encoding genes in GH-transgenic fish specifically.

156 tran sodium sulfate-induced colitis model in GH-overexpressing mice.

157 ted from ksr2(-/-) mice show no reduction in GH-stimulated STAT5 phosphorylation.

158 elop intestinal and colon tumors resulted in GH-deficient double mutants with markedly decreased tumo

159 al air toxics before conception may increase GH risk.

160 GH-releasing hormone (GHRH) analog increased GH production and DNA damage measured by H2AX phosphoryl

161 BD reduced circulating GH and increased GH levels only in steatotic livers.

162 However, EGF increased GH in nonsteatotic grafts, which exacerbated damage.

163 ls or in the entire brain markedly increased GH pulse secretion and body growth in both male and fema

164 For an interquartile-range increment, GH risk was significantly increased by 18% for sulfur di

165 Our findings indicate GH as a starvation signal that alerts the brain about en

166 t male mice that received an intraperitoneal GH injection.

167 t of POU1F1 in dominantly inherited isolated GH deficiency and demonstrates a significant impact of t

168 rmined that Salmonella required two keystone GHs for internalization, and left remodeled host glycans

169 mbinase technology to produce mice that lack GH receptors selectively in liver (L-Ghr (-/-) mice) or

170 As for other large GH families (i.e. GH5, GH13, and GH43), this new subfami

171 The largest GH identified so far in this genus, Calkro_0111 (2,435 a

172 ylococcal pore-forming cytotoxin, leukocidin GH (LukGH), in complex with its receptor (the alpha-I do

173 ester in Pakistani women resulted in a lower GH rate, whereas PE rates, influenced by the steep third

174 c screened 6 MOS sensors (LY2/G, LY2/AA, LY2/GH, LY2/gCT1, T30/1, and P30/1) to deconvolute the ranci

175 in death (BD), and the effects of modulating GH through exogenous epidermal growth factor (EGF) in st

176 e observed that the bioactivity of monomeric GH-C53S is 25.2% of that of GH-WT and that dimeric GH-C5

177 has been reported previously that monomeric GH-C53S has reduced bioactivity compared with WT GH (GH-

178 Reconcilibacillus cellulovorans' multidomain GHs assembled into cellulase complexes through glycosyla

179 of serum growth hormone (GH) during natural GH cycles.

180 ing us to propose the establishment of a new GH family, designated GH161.

181 was 1.57 (95% CI, 1.04-2.39) after GH vs no GH.

182 and 5.08 (95% CI, 1.80-14.34) after GH vs no GH.

183 Compared with having neither GDM nor GH, having either was associated with incident diabetes

184 Approximately 51% of GH-responsive cells in the PVH co-localized with the ves

185 that mediate this effect and the ability of GH to inhibit insulin-stimulated glucose uptake have sca

186 Mice carrying ablation of GH receptor (GHR) either in leptin receptor (LepR)- or s

187 Ablation of GH receptor (GHR) from TH cells or in the entire brain m

188 GH receptor, suggesting the direct action of GH on these cells.

189 GH resistance results from direct actions of GH on lipid uptake and de novo lipogenesis, whereas its

190 Administration of GH and EGF and their underlying mechanisms were characte

191 bone deformities, whereas the association of GH and MAPK inhibition emerges as a promising new therap

192 r DBH are required for the autoregulation of GH secretion via a negative-feedback loop.

193 Pharmacological blockade of GH signaling prevented the development of the phenotype.

194 wed that the SST/CORT role in the control of GH/prolactin secretions is maintained under LF- and HF-d

195 n POU1F1 present with combined deficiency of GH, PRL and TSH.

196 regnancy, irrespective of the development of GH or PE or presence of a risk factor.

197 current overview of the lipolytic effect of GH in humans, mice and cultured cells.

198 Thus, the growth-promoting effect of GH is likely linked to increased risk of bone deformitie

199 are presented for the differential effect of GH on specific adipose tissue depots and on distinct cla

200 pathways regulating the metabolic effects of GH on adipose tissue.

201 rated phenotypic and biochemical evidence of GH excess including significantly elevated insulin-like

202 We also found that the expression of GH-C53S in pituitary cells deviates from that of GH-WT.

203 ed analysis of the neurochemical identity of GH-responsive cells to understand the possible physiolog

204 and IFNgamma, and 2) to assess the impact of GH on key macrophage functional properties like reactive

205 bal transcriptional and functional impact of GH on macrophage programming, bone marrow derived macrop

206 and the possible physiological importance of GH action on PVH neurons.

207 growth criteria, we recommend initiation of GH therapy 1 year after transplantation if spontaneous c

208 In this study, we investigated the levels of GH, IGF-1 and IGF-binding protein 2 (IGFBP-2) after gast

209 In contrast to the vast majority of GH, the catalytic apparatus of BT3686 does not comprise

210 were associated with a 60% increased odds of GH, and a 37% reduced odds of SGA; PTH was associated wi

211 sociated with a 45% reduction in the odds of GH.

212 The notable overlap of GH with IFNgamma-induced pathways involved in innate imm

213 ng in the preclinical and clinical phases of GH and preeclampsia.

214 The regulation of GH secretion relies on the ability of these cells to sen

215 cantly associated with 8%-20% higher risk of GH.

216 ne (GH) receptor (GHR), although the role of GH signaling on PVH neurons is still unknown.

217 Analysis of sequences of GH-ligand complexes reveals that side chain restriction

218 To determine the site of GH action, in the current study we used CRISPR/Cas9 and

219 de that the impaired metabolism in states of GH resistance results from direct actions of GH on lipid

220 We demonstrate early-onset suppression of GH release in rapidly growing MC4R deficient (MC4RKO) mi

221 e globally, we explain lipolysis in terms of GH-induced intracellular signalling and its effect on ob

222 ity of monomeric GH-C53S is 25.2% of that of GH-WT and that dimeric GH-C53S-His has no significant bi

223 53S in pituitary cells deviates from that of GH-WT.

224 ical practice recommendations for the use of GH in children with CKD on dialysis and after renal tran

225 fication of the multi-domain architecture of GHs from various datasets.

226 role in normal renal function and overactive GH signaling has been implicated in proteinuria in diabe

227 ral, sex-biased gene responses to persistent GH stimulation are dictated by GH/STAT5-regulated transc

228 in circulating GH levels to adjust pituitary GH secretion within a narrow physiological range.

229 IA-602, at a dose that did not affect plasma GH levels, significantly reduced TRL, as well as markers

230 inistration of a MAPK pathway inhibitor plus GH was the most beneficial treatment because of the posi

231 ighly purified lyophilized pituitary porcine GH treatment (0.6 mg/day); Group-3 (positive control) im

232 in prohormone processing of proinsulin, pro-GH-releasing hormone, and proghrelin in association with

233 a complex multistep mechanism of processive GHs.

234 us polyposis coli (APC), reversing progrowth GH signals.

235 Exogenous EGF reduced GH in steatotic livers, thus activating cell proliferati

236 lin, and GH-releasing hormones that regulate GH secretion from the anterior pituitary were determined

237 -expressing neurons are required to regulate GH secretion via negative-feedback mechanisms is unknown

238 p between host genetics, dose of the at-risk GH, age at treatment onset, and duration of the incubati

239 Growth hormone-secreting (GH-secreting) pituitary tumors are driven by oncogenes t

240 fected by SCNAs in growth hormone-secreting (GH-secreting) somatotroph adenomas.

241 Since GH plays a key role in cell proliferation, body growth,

242 As a result, some GH families, including alpha-amylases (GH13), have their

243 ion of several pituitary hormones (specially GH/PRL), which was accompanied by increased sst2/sst5/D2

244 Specifically, GH treatment of GM-CSF-primed monocyte-derived macrophag

245 inhibited GHRH-, but not ghrelin-stimulated GH-secretion.

246 Leptin and resistin stimulated GH-release, a response that was blocked by somatostatin.

247 population-based retrospective cohort study, GH was identified in matched pairs of mothers with GDM o

248 Systemic GH (12.32 vs. 50.97 pg/mL, p < 0.001) and IGFBP-2 levels

249 Specifically targeting GH secretion rather than somatotroph proliferation may b

250 b. bone deficit than mild TBI alone and that GH anabolic effects in the TBI and UL groups vary depend

251 spectively compared to Control mice and that GH treatment significantly increased Tb. bone mass in al

252 We conclude that GH acts through its receptor in the liver to activate au

253 Therefore, we tested the hypothesis that GH treatment will rescue the hind limb unloading (UL)-in

254 These findings support the hypothesis that GH-therapy enhances axonal regeneration and maintains ch

255 Overall, these data indicate that GH reprograms inflammatory macrophages to an anti-inflam

256 We propose that GH is a molecular component of the "field change" milieu

257 Here we report that GH treatment limited to a few weeks during development i

258 In this study, we show that GH regulates the phenotypic and functional plasticity of

259 lumen of phagosomes, we have also shown that GH alters physiologically relevant processes such as ROS

260 Our findings suggest that GH action on PVH neurons is involved in the regulation o

261 This study determined that GHs recognize the terminal monosaccharides (N-acetylneur

262 s decreased ability to bind and activate the GH receptor in vitro In this study, we discovered that s

263 ential role in renal filtration, express the GH receptor, suggesting the direct action of GH on these

264 y the size of the GH but also changes in the GH over time.

265 ficiency resulted in severe steatosis in the GH(tg) background.

266 described the initial size and slope of the GH as a function of prolapse status (case vs. control) a

267 considered to be a primary oscillator of the GH axis, we examined its acute effects on GHRH neurons i

268 rs could evaluate not simply the size of the GH but also changes in the GH over time.

269 warf mice show that this short period of the GH exposure during early development produces persistent

270 the mean rate of increase in the size of the GH was more than 3 times greater (0.56 cm per 5-year per

271 ur in response to enhanced activation of the GH-IGF-1 axis.

272 novel mechanism involving activation of the GH-Stat5 signaling pathway.

273 (DMP-GHRKO) mice to address the role of the GH/IGF axis in osteocytes.

274 and TBI-UL groups at day 14, suggesting the GH effect on liver IGF-I production was unaffected by sk

275 We conclude that the GH-C53S dimer is inactive and responsible for the growth

276 In this model, in addition to the GH-mediated effects on other immune cells, we observed t

277 ed conformations for the EF loop of VP2, the GH loop of VP3, and the N-terminal extensions of VP1 and

278 led that novel binding interactions with the GH loop, rather than the DE loop, are energetically crit

279 females potentially by interacting with the GH/IGF-1 axis.

280 Therapeutically, GH supplementation was able to correct growth retardatio

281 This represents a new activity in this GH family and a potentially useful new enzyme class for

282 lant from BD donors, whereas EGF (throughout GH inhibition) protects only in steatotic grafts.

283 r reduced longevity of dwarf mice exposed to GH treatment early in life.

284 ibutional uniformity index (DUI), related to GH and DH indices, respectively.

285 eption and in early gestation in relation to GH risk in the Consortium on Safe Labor/Air Quality and

286 e TH, TRH and CRH neurons were responsive to GH in the PVH of Fluoro-Gold-injected mice.

287 (TH) cells, respectively, were responsive to GH in the PVH.

288 Similar to GH(tg)STAT5(Deltahep) mice, JAK2 deficiency resulted in

289 responsive genes included those encoding two GH/STAT5-regulated transcriptional repressors: male-bias

290 the M5nr data and identified 322,068 unique GHs.

291 ha7) of SCARB2 and the viral protein 1 (VP1) GH and VP2 EF loops of EV71 dominate the interaction, su

292 However, whether GH modulates the CRR to hypoglycemia via specific neuron

293 gs that define molecular mechanisms by which GH induces lipolysis are described.

294 res for 6,074 singleton pregnancies in which GH was present and 199,980 normotensive pregnancies.

295 of MAPK inhibition alone or associated with GH on growth and growth plate and bone structure of youn

296 domains never identified in association with GH.

297 marrow derived macrophages were treated with GH or IFNgamma.

298 ofile of macrophages activated in vitro with GH and IFNgamma, and 2) to assess the impact of GH on ke

299 ntified 36 studies, including 745 women with GH and 815 women with preeclampsia.

300 kistani compared to white British women with GH and PE showed steeper BP increases towards the end of

301 53S has reduced bioactivity compared with WT GH (GH-WT) because of its decreased ability to bind and